Nanomedicine: history keeps the EU on the verge of a revolution
This article was originally published in Clinica
Europe is on the edge of a technological revolution in the area of nanomedicine. There are already plenty of products in the pipeline, and some are commercially available, although significantly fewer than in the US which is way ahead of the EU in this area. So what is holding the EU back? Amanda Maxwell attended the recent nanotechnology conference, organised by the UK Medicines and Healthcare products Regulatory Agency (MHRA), on October 27, organised as part of the UK's EU Council presidency programme to find out
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.